

ABSTRACT

This study surveyed clinical practices for **GammaTile®** Cs-131 intracranial brachytherapy across 15 U.S. institutions to characterize inter-institutional variability and identify opportunities for standardization and quality assurance. An anonymous 55-question survey was sent to medical physicists covering personnel involvement, workflows, imaging, contouring, dosimetry, quality assurance, and radiation safety.

Key Findings:

- Medical physicists routinely participate in tile estimation and ordering.
- Pre-operative practices showed notable variability in imaging requirements (T1-weighted MRI required in most centers), tile-count estimation methods (mostly GT lookup table) ordering lead times, and seed-use policies.
- Independent seed strength verification was common, primarily using well chambers or dose calibrators.
- Post-implant resection cavity contouring was nearly universal, but substantial variability existed in delineation methods, imaging protocols (MRI/CT), margin application (0–5 mm), target volume definition, and inclusion of residual enhancing disease.
- Target V100 and D90 reporting were relatively consistent, while organs-at-risk dose reporting and secondary independent TPS dose verification were inconsistent or rare.
- Radiation safety practices were more uniform in some areas (e.g., pregnancy time-outs) but varied in personal protective equipment use and patient release recommendations.

The survey revealed considerable variability in pre-operative imaging/ordering, post-implant planning, and certain quality assurance steps, highlighting key areas where standardization could improve consistency, safety, and quality in GammaTile programs.

Scan the QR code to participate on this survey



CONTACT

Clara Ferreira, PhD
cferreir@umn.edu

A National Multi-Institutional Survey Of Comprehensive Workflow And Quality Assurance In Cs-131 GammaTile Implants For Intracranial Tumors

Clara Ferreira, PhD¹, Mark J. Rivard, PhD², Karl H. Rasmussen, PhD³, Surendra Prajapati, PhD⁴, Hualin Zhang, PhD⁵, Wesley A. Belcher, PhD⁶, Rajeev K. Badkul, MS⁷, Grace Weber¹, Grace Burkholder¹, Tarun K. Podder, PhD⁸, Wenzheng Feng, MS⁹, Antonio L. Damato¹⁰, David Aramburu Nunez, PhD¹⁰, Rajat J. Kudchadker, PhD¹¹, Daniel J. Scanderbeg, PhD¹², Ranjini P. Tolakanahalli, PhD¹³ and Vibha Chaswal, PhD¹³, ¹University of Minnesota, Minneapolis, MN, ²Brown University, Providence, RI, ³UT Health San Antonio, San Antonio, TX, ⁴Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Southern California, Los Angeles, CA, ⁶East Carolina University Brody School of Medicine, Greenville, NC, ⁷Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, ⁸SUNY Upstate Medical University, Syracuse, NY, ⁹Hackensack Meridian Health, Neptune, ¹⁰Memorial Sloan Kettering Cancer Center, New York, NY, ¹¹The University of Texas MD Anderson Cancer Center, Houston, TX, ¹²University of California San Diego, San Diego, CA, ¹³Miami Cancer Institute, Baptist Health South Florida, Miami, FL

INTRODUCTION

GammaTile® Cs-131 intracranial brachytherapy requires coordinated interdisciplinary efforts across pre-operative imaging, source ordering/verification, intra-operative procedures, post-implant planning, and radiation safety. However, the extent of inter-institutional variability in these practices remains undefined. This study characterizes current practices to identify areas of consistency and variability relevant to quality assurance and standardization.


METHODS AND MATERIALS

An anonymous 55-question survey addressing personnel involvement, workflow practices, pre- and post-operative imaging, contouring, dosimetry and treatment planning, quality assurance, and radiation safety was distributed to medical physicists at 15 U.S. institutions with active GammaTile programs. Responses were analyzed to characterize current practices.

RESULTS

Medical physicists routinely participated in tile estimation and tile order (80%). Pre-operative imaging showed variability: T1-weighted MRI was required in 83.3% of centers, often with 1–2 mm slice thickness. Tile count estimation primarily used the GT lookup table (66.7%). Minimum ordering lead-time policies existed in 86.7% of centers, but allowable seed-use delays varied (0–2 days), and pre-op MRI validity ranged from 7–30 days. Independent seed strength verification occurred in 93.4% of centers using ADCL-calibrated reentrant well chambers (66.7%) or cross-calibrated dose calibrators (26.7%); 58.3% reviewed vendor assay reports. Post-operative resection cavity contouring was nearly universal (91.6%), but substantial variability existed in delineation methods, imaging protocols (MRI/CT), contour naming, target volume definition, margin application (0–5 mm), and inclusion of residual enhancing disease. Target V100, and D90 reporting were relatively consistent, while organs-at-risk dose reporting were inconsistent (25.0% always, 75.0% optional). Secondary independent TPS-dose verification was rare (16.7%). Radiation safety practices showed more consistency (e.g., pregnancy-related time-outs in most centers), and greater variability shown in personal protective equipment use, and patient release recommendations.

RESULTS



DISCUSSION

This survey of 15 U.S. institutions highlights substantial practice variability in GammaTile® Cs-131 brachytherapy. While physicist participation in tile ordering (75%) and post-implant cavity contouring (92%) are highly consistent, major differences exist in pre-operative imaging protocols, tile estimation methods, margin selection (0–5 mm), target volume definitions, and inclusion of residual disease. Organs-at-risk reporting and secondary dose verification remain inconsistent or rare (17%). Because GammaTile dosimetry is largely determined intraoperatively, such variability may affect treatment reproducibility and quality. Radiation safety practices were more uniform, but opportunities remain for standardization.

CONCLUSIONS

This multi-institutional survey showed substantial variability in pre-operative imaging requirements, ordering policies, post-implant planning practices, and secondary quality assurance. These findings identify clinical aspects where standardization could enhance quality assurance and consistency.

REFERENCES

- Clara Ferreira et al. First clinical implementation of GammaTile permanent brain implants after FDA clearance, Brachytherapy, 2021 May-Jun;20(3):673-685.
- Gregory P Penoncello et al., Comprehensive Commissioning and Clinical Implementation of GammaTiles STaRT for Intracranial Brain Cancer, Adv Radiat Oncol, 2022 Feb 5;7(4)